Zynext Ventures acquires stake in Agenus, expands its immuno-oncology pipeline and global reach
The investment underscores Zynext Ventures' commitment to advancing innovation in critical therapeutic areas.
PENNINGTON, N.J., June 3, 2025 /CNW/ -- Zynext Ventures USA LLC (Zynext), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Agenus Inc., a leading US-based immuno-oncology company developing next-generation therapeutics for high-unmet need cancers.
Agenus' lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.
"Our investment in Agenus aligns perfectly with our vision to advance life-changing therapies and offer novel solutions anchored on science, innovation and health to empower patients," said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences. "Our extensive global partner network will also play a key role in supporting Agenus' entry into new indications and geographies, allowing these innovative therapies to reach more patients, faster. This collaboration will help propel Agenus' programmes and unlock their full potential."
In addition to capital, Zynext Ventures will bring deep expertise in data analytics and access to a broad global network of biotech, regulatory, and clinical partners. This synergistic approach aims to unlock new avenues for Agenus, enabling the company to broaden the application of its BOT/BAL programme into earlier lines of treatment and address a wider spectrum of cancers with significant unmet medical needs.
Dr. Garo Armen, Chairman and CEO of Agenus, said, "We are delighted to partner with Zynext Ventures in a truly synergistic relationship. BOT/BAL's remarkable results across nine distinct cancers, in both late-stage and neoadjuvant settings, inspire us to push the boundaries of what is possible in oncology. Zydus' commercial reach and expertise make them an ideal partner to accelerate the delivery of this potentially transformative therapy."
About Zynext Ventures
Zynext Ventures is the investment arm of Zydus Lifesciences. The venture capital firm focuses on identifying and investing in promising early-stage and growth-stage companies in the healthcare sector. Zynext Ventures provides financial support, strategic guidance, and industry expertise to its portfolio companies, helping them achieve their full potential and make a meaningful impact on the lives of patients.
For more details visit: www.zynextventures.com
LinkedIn: Zynext Ventures
Twitter: @ZynextVentures
About Zydus
Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 27,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars.
For more details visit: www.zyduslife.com.
LinkedIn: @Zydusuniverse
Instagram: @ZydusUniverse
About Agenus
Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. Leveraging proprietary scientific platforms, the company's pipeline includes multiple checkpoint antibody candidates, vaccines, and cell therapies. Headquartered in Lexington, MA, Agenus operates globally, driving innovations to bring better cancer treatments to patients.
For more details visit: www.agenusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the planned collaboration, the development and commercialization of BOT/BAL, and anticipated timelines. Actual results may differ due to various risks and uncertainties, including regulatory approvals and other factors. Readers are encouraged to review each company's public filings for additional information regarding potential risks and timelines.
Logo: https://mma.prnewswire.com/media/2442038/5213236/Zynext_Ventures_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/zynext-ventures-acquires-stake-in-agenus-expands-its-immuno-oncology-pipeline-and-global-reach-302472002.html
SOURCE Zynext Ventures
View original content: http://www.newswire.ca/en/releases/archive/June2025/03/c4821.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
XAI Madison Equity Premium Income Fund Will Host its Q2 2025 Quarterly Webinar on August 7, 2025
CHICAGO, July 24, 2025 (GLOBE NEWSWIRE) -- XAI Madison Equity Premium Income Fund (NYSE: MCN) (the 'Fund') today announced that it plans to host the Fund's Quarterly Webinar on August 7, 2025 at 11:00 am (Eastern Time). Jared Hagen, Vice President at XA Investments ('XAI') will moderate the Q&A style webinar with Kimberly Flynn, President at XAI, and Ray Di Bernardo, Portfolio Manager at Madison Investments. TO JOIN VIA WEB: Please go to the Knowledge Bank section of or click here to find the online registration link. TO USE YOUR TELEPHONE: After joining via web, if you prefer to use your phone for audio, you must select that option and call in using a number below, based on your current location. Dial: (312)-626-6799 or (646)-558-8656 or (267)-831-0333 or (720)-928-9299 or (213)-338-8477Webinar ID: 818 2684 2773 REPLAY: A replay of the webinar will be available in the Knowledge Bank section of The Fund's primary investment objective is to provide a high level of current income and gains, with a secondary objective of capital appreciation. The Fund pursues its investment objectives by investing in a portfolio consisting primarily of high quality, large and mid-capitalization stocks that are, in the view of the Fund's Investment sub-adviser, selling at a reasonable price in relation to their long-term earnings growth rates. The Fund will, on an ongoing and consistent basis, sell covered call options on its portfolio stocks to seek to generate current earnings from option premiums. There can be no assurance that the Fund will achieve its investment objectives. The Fund's common shares are traded on the New York Stock Exchange under the symbol MCN. About XA Investments XA Investments LLC ('XAI') is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund, respectively the XAI Octagon Floating Rate & Alternative Income Trust, the XAI Madison Equity Premium Income Fund, and the Octagon XAI CLO Income Fund. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including product development and market research, marketing and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. For more information, please visit About XMS Capital Partners XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit About Madison Investments Madison Investments (Madison) is an independent investment management firm based in Madison, Wisconsin. The firm was founded in 1974, has approximately $28 billion in assets under management as of March 31, 2025, and is recognized as one of the nation's top investment firms. The firm has managed covered call strategies for over 20 years through various market cycles. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance, and credit union investment management strategies. For more information, please visit XAI does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax. Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Trust carefully before investing. For more information on the Trust, please visit the Trust's webpage at This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction. NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE Paralel Distributors, LLC - Distributor Media Contact: Kimberly Flynn, President XA Investments LLCPhone: 312-374-6931Email: kflynn@
Yahoo
26 minutes ago
- Yahoo
S&P/TSX composite closes lower on Thursday, U.S. markets mixed
TORONTO — Losses in basic materials and consumer cyclicals helped drive Canada's main stock index to finish lower on Thursday, while U.S. markets were mixed. The S&P/TSX composite index was down 44.15 points at 27,372.26. In New York, the Dow Jones industrial average was down 316.38 points at 44,693.91. The S&P 500 index was up 4.44 points at 6,363.35, while the Nasdaq composite was up 37.94 points at 21,057.96. The Canadian dollar traded for 73.37 cents US compared with 73.48 cents US on Wednesday. The September crude oil contract was up 78 cents US at US$66.03 per barrel. The August gold contract was down US$24.10 at US$3,373.50 an ounce. This report by The Canadian Press was first published July 24, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Intel to slash workforce by year-end as it forecasts steeper losses than expected
By Arsheeya Bajwa, Stephen Nellis and Max A. Cherney (Reuters) -Intel said on Thursday it plans to slash its headcount to 75,000 by the end of this year, down from 99,500 at the end of 2024. Shares of Intel jumped roughly 3.8% in extended trading. The Santa Clara, California-based chipmaker disclosed the layoff goals as it forecast steeper third-quarter losses than Wall Street estimates on Thursday, despite anticipating higher sales than analysts expected while new CEO Lip-Bu Tan steers the company through a historic turnaround. The outlook comes as investors pushed Intel's shares up 14% this year, in the hopes of Tan undoing years of strategic mistakes that have exempted the company from the AI boom dominated by Nvidia. The company said it expects a third-quarter loss of 24 cents per share, steeper than estimates of losses of 18 cents per share, according to data from LSEG. Intel expects revenue of $12.6 billion to $13.6 billion for the September quarter, with a midpoint of $13.1 billion that was higher than analysts' average estimate of $12.65 billion, according to data compiled by LSEG. Growth in the PC market is uncertain after customers pulled shipments forward to the first half of the year amid ongoing trade negotiations, analysts have said. Shipments of PCs rose 6.5% in the June quarter according to data from International Data Corporation. While semiconductors are currently exempt from U.S. President Donald Trump's sweeping global tariffs, Intel and its fellow chipmakers are facing customers who are reluctant about spending commitments amid widespread macroeconomic uncertainty. Intel's second-quarter revenue for the period ended June 28 was flat at $12.9 billion, snapping a four-quarter streak of sales declines. The result beat estimates of $11.92 billion, according to LSEG data. CEO Tan has been focusing on a next-generation chipmaking process called 14A to win big external customers, shifting away from 18A, a technology that his predecessor Pat Gelsinger had spent billions of dollars to develop, Reuters has reported. Tan has also focused on streamlining the organization and reducing its workforce. In April, Intel agreed to sell a 51% stake in its Altera programmable chip business for $4.46 billion. Intel said job cuts contributed to restructuring costs of $1.9 billion in the second quarter. It recorded June quarter adjusted losses of 10 cents per share, compared with estimates of a profit of 1 cent per share. Its unadjusted loss was 67 cents per share in the second quarter, steeper than analyst estimates of a 26-cent-per-share loss. Sign in to access your portfolio
